Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 52005XC0527(01)

    Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 April 2005 to 15 May 2005(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

    JO C 130, 27.5.2005, p. 5–7 (ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, NL, PL, PT, SK, SL, FI, SV)

    27.5.2005   

    EN

    Official Journal of the European Union

    C 130/5


    Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 April 2005 to 15 May 2005

    (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93) (1)

    (2005/C 130/04)

    —   Modification of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93): Accepted

    Date of the decision

    Name of the medicinal product

    Holder of the marketing authorisation

    Number of the entry in the Community Register

    Date of notification

    20.4.2005

    Velcade

    Janssen-Cilag International NV, Turnhoutseweg, 30 — B-2340 Beerse

    EU/1/04/274/001

    22.4.2005

    20.4.2005

    Viramune

    Boehringer Ingelheim International GmbH, Binger Strasse 173 — D-55216 Ingelheim am Rhein

    EU/1/97/055/001-002

    22.4.2005

    20.4.2005

    Paxene

    Norton Healthcare Limited, Albert Basin, Royal Docks, London E16 2QJ, United Kingdom

    EU/1/99/113/001-004

    22.4.2005

    25.4.2005

    Zeffix

    Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom

    EU/1/99/114/001-003

    27.4.2005

    25.4.2005

    HBVAXPRO

    Sanofi Pasteur MSD, SNC, 8, rue Jonas Salk, F-69007 Lyon

    EU/1/01/183/001-019

    27.4.2005

    25.4.2005

    Humira

    Abbott Laboratories Ltd, Queenborough, Kent ME11 5EL, United Kingdom

    EU/1/03/256/001-006

    27.4.2005

    25.4.2005

    GONAL f

    Serono Europe Limited, 56, Marsh Wall, London E14 9TP, United Kingdom

    EU/1/95/001/001-035

    27.4.2005

    25.4.2005

    Trudexa

    Abbott Laboratories Ltd, Queenborough, Kent ME11 5EL, United Kingdom

    EU/1/03/257/001-006

    27.4.2005

    27.4.2005

    Viagra

    Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom

    EU/1/98/077/001-012

    29.4.2005

    27.4.2005

    Keppra

    UCB SA, Allée de la recherche, 60, B-1070 Bruxelles

    Researchdreef, 60, B-1070 Brussel

    EU/1/00/146/001-027

    29.4.2005

    27.4.2005

    Lantus

    Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main

    EU/1/00/134/012

    29.4.2005

    27.4.2005

    Optisulin

    Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main

    EU/1/00/133/008

    29.4.2005

    27.4.2005

    Forsteo

    Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland

    EU/1/03/247/001-002

    29.4.2005

    27.4.2005

    Neupopeg

    Dompé Biotec SpA, Via San Martino, 12, I-20122 Milano

    EU/1/02/228/001-002

    29.4.2005

    27.4.2005

    Cellcept

    Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom

    EU/1/96/005/001-006

    29.4.2005

    27.4.2005

    Carbaglu

    Orphan Europe, Immeuble ‘Le Guillaumet’, F-92046 Paris La Défense

    EU/1/02/246/001-003

    29.4.2005

    28.4.2005

    Herceptin

    Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom

    EU/1/00/145/001

    3.5.2005

    28.4.2005

    Emend

    Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom

    EU/1/03/262/001-006

    3.5.2005

    28.4.2005

    Emend

    Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom

    EU/1/03/262/001-006

    3.5.2005

    28.4.2005

    Enbrel

    Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom

    EU/1/99/126/006-011

    3.5.2005

    28.4.2005

    Rapamune

    Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom

    EU/1/01/171/001-012

    3.5.2005

    29.4.2005

    Neulasta

    Amgen Europe BV, Minervum 7061, 4817 ZK Breda, Nederland

    EU/1/02/227/001-002

    3.5.2005

    10.5.2005

    Lyrica

    Pfizer Ltd; Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom

    EU/1/04/279/001-025

    13.5.2005

    10.5.2005

    Cancidas

    Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom

    EU/1/01/196/001-003

    13.5.2005

    13.5.2005

    Apidra

    Aventis Pharma Deutschland GmbH, Brueningstraße 50, D-65926 Frankfurt am Main

    EU/1/04/285/001-028

    18.5.2005

    —   Withdrawal of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93)

    Date of the decision

    Name of the medicinal product

    Holder of the marketing authorisation

    Number of the entry in the Community Register

    Date of notification

    25.4.2005

    Infanrix Hep B

    GlaxoSmithKline Biologicals SA, rue de l'Institut 89, B-1330 Rixensart

    EU/1/97/048/001-014

    27.4.2005

    —   Modification of a marketing authorisation (Article 34 of Council Regulation (EEC) No 2309/93): Accepted

    Date of the decision

    Name of the medicinal product

    Holder of the marketing authorisation

    Number of the entry in the Community Register

    Date of notification

    18.4.2005

    Bayovac CSF E2

    Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom

    Bayer AG, Geschäftsbereich Tiergesundheit, D-51368 Leverkusen

    EU/2/00/025/001-004

    20.4.2005

    21.4.2005

    Eurifel FeLV

    Merial, 29 Avenue Tony Garnier, F-69007 Lyon

    EU/2/00/019/001-003

    27.4.2005

    27.4.2005

    Ibraxion

    Merial, 29 avenue Tony Garnier, F-69007 Lyon

    EU/2/99/017/001-006

    29.4.2005

    27.4.2005

    Metacam

    Boehringer Ingelheim Vetmedica GmbH, D-55216 Ingelheim am Rhein

    EU/2/97/004/001

    EU/2/97/004/003-010

    29.4.2005

    Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

    The European Medicines Agency

    7, Westferry Circus, Canary Wharf

    London E14 4HB

    United Kingdom


    (1)  OJ L 214 of 24.8.1993, p. 1.


    Top